Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia Long-term follow-up of a prospective multicenter trial (1995)
    Springer
    Annals of hematology 71 (1995), S. 219-225 
    Details
    ISSN: 1432-0584
    Keywords: Key words De novo AML ; Adults ; HD-Ara-C/DNR consolidation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  A total of 149 consecutive de novo AML patients aged 50 years or less (median age = 37 years) were enrolled in this prospective multicenter trial initiated in May 1985. All patients received the same induction and early consolidation therapy with daunorubicin (DNR), cytosine arabinoside (Ara-C), and etoposide (DAV). High-dose Ara-C/DNR therapy included Ara-C at 3 g/m2, in 12 doses (HD-Ara-C/DNR I) and eight doses (HD-Ara-C/DNR II), followed by DNR 30 mg/m2 for 3 days. A complete remission (CR) was achieved in 104 (70%) patients; 61 complete responders received at least one cycle with HD-Ara-C/DNR. If those patients who were transplanted in first CR (n = 26), were not considered, the median relapse-free-survival (MRFS) of the remaining 78 patients was 15 months, with a probability of relapse-free survival (RFS) at 116 months of 30% (95% CI, 20–40%) after a median follow-up of 95 months. The MRFS of the HD-Ara-C/DNR consolidated patients was 25 months, with a probability of RFS at 116 months of 37% (95% CI, 24–50%). If all patients who were transplanted (n = 44) were not considered, the median survival time (MST) was 18 months with a probability of being alive at 118 months of 24% (95% CI, 16–33%). MST of the HD-Ara-C/DNR consolidated patients was 58 months with a survival probability of 46% (95% CI, 31–60%) at 118 months. Prognostic factor analysis did not reveal any significant influence of age, sex, FAB subtype, white blood cell count, hemoglobin level, thrombocyte count, LDH, or response to the first induction course on RFS of the HD-Ara-C/DNR consolidated patients. In summary, HD-Ara-C/DNR consolidation can improve the long-term outcome of a subgroup of de novo AML patients. Further improvement of the outcome seems to depend on the identification of patients with an inferior outcome under that strategy who might benefit from alternative treatment strategies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01744371
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia (1995)
    Springer
    Annals of hematology 71 (1995), S. 219-225 
    Details
    ISSN: 1432-0584
    Keywords: De novo AML ; Adults ; HD-Ara-C/DNR consolidation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract A total of 149 consecutive de novo AML patients aged 50 years or less (median age = 37 years) were enrolled in this prospective multicenter trial initiated in May 1985. All patients received the same induction and early consolidation therapy with daunorubicin (DNR), cytosine arabinoside (Ara-C), and etoposide (DAV). High-dose Ara-C/DNR therapy included Ara-C at 3 g/m2, in 12 doses (HD-Ara-C/DNR I) and eight doses (HD-Ara-C/DNR II), followed by DNR 30 mg/m2 for 3 days. A complete remission (CR) was achieved in 104 (70%) patients; 61 complete responders received at least one cycle with HD-Ara-C/DNR. If those patients who were transplanted in first CR (n=26), were not considered, the median relapsefree-survival (MRFS) of the remaining 78 patients was 15 months, with a probability of relapse-free survival (RFS) at 116 months of 30% (95% CI, 20–40%) after a median follow-up of 95 months. The MRFS of the HD-Ara-C/DNR consolidated patients was 25 months, with a probability of RFS at 116 months of 37% (95% CI, 24–50%). If all patients who were transplanted (n=44) were not considered, the median survival time (MST) was 18 months with a probability of being alive at 118 months of 24% (95% CI, 16–33%). MST of the HD-Ara-C/DNR consolidated patients was 58 months with a survival probability of 46% (95% CI, 31–60%) at 118 months. Prognostic factor analysis did not reveal any significant influence of age, sex, FAB subtype, white blood cell count, hemoglobin level, thrombocyte count, LDH, or response to the first induction course on RFS of the HD-Ara-C/DNR consolidated patients. In summary, HD-Ara-C/DNR consolidation can improve the long-term outcome of a subgroup of de novo AML patients. Further improvement of the outcome seems to depend on the identification of patients with an inferior outcome under that strategy who might benefit from alternative treatment strategies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01744371
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Impaired T-cell and NK-cell function in patients with preleukemia (1982)
    Springer
    Annals of hematology 45 (1982), S. 243-248 
    Details
    ISSN: 1432-0584
    Keywords: Preleukemia ; T-cell mitogens ; NK cell activity ; Immune functions
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The responses to the T-cell mitogens Phythemagglutinin (PHA) and Concanavalin A (ConA) and the natural killer (NK) cell activity are tested in patients with preleukemia (PL). The results are compared with those of healthy controls. The PL patients show low responses to T-cell mitogens and low NK cell activities. It is discussed that the data are not of prognostic value in PL as to development of overt leukemia. However, the results suggest that in PL impaired cell functions are not limited to erythropoiesis, granulopoiesis, and thrombopoiesis but are also found in the immune system.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00320191
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Verlauf und prognostische Kriterien bei Patienten mit „Präleukämie“ (1979)
    Springer
    Journal of molecular medicine 57 (1979), S. 21-29 
    Details
    ISSN: 1432-1440
    Keywords: Preleukemia ; Acute leukemia ; Prospective study ; Präleukämie ; Akute Leukämie ; Prospektive Studie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung In einer prospektiven, multizentrischen Studie wurde der Verlauf bei 33 Patienten mit Präleukämie verfolgt. Kriterien für die Aufnahme in die Studie waren eine Anämie mit Granulo- und/oder Thrombozytopenie bei normal oder erhöht zellreichem Knochenmark und Ausschluß einer für diese Veränderungen verantwortlichen Grunderkrankung oder externen Noxe. Die kürzeste Nachbeobachtungszeit nach Stellung der Diagnose „Präleukämie“ betrug 3 Jahre. Die mediane Überlebenszeit war 26 Monate nach Ersterfassung und 36 Monate nach Erstsymptom der Erkrankung. Remissionen wurden nicht beobachtet. Bei 40% der Patienten wurde innerhalb von 2 Jahren nach Ersterfassung eine akute Leukämie diagnostiziert. Unter den geprüften prognostischen Faktoren sprachen vor allem Chromosomenaberrationen und ein erhöhter Blastenanteil für den Übergang in eine akute Leukämie.
    Notes: Summary The natural course of disease was followed in 33 patients with so-called preleukemia by a prospective multicentric protocol. Patients with the following criteria were included: Anaemia with granulocytopenia and/or thrombocytopenia, normal or increased cellularity of the bone marrow and exclusion of a known diagnosis of underlying disease. Follow up after assumption of “preleukemia” was 3 years or more. Median survival was 26 months after diagnosis of preleukemia and 36 months after the first unequivocal symptoms of the blood dyscrasia. 40% of the patients changed to the picture of leukemia within 2 years. The most important parameters suggesting subsequent transition to overt leukemia where chromosomal abberations and an increased blast count of the bone marrow.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01476978
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    The use of 99m-Tc-Pertechnetate for the determination of red cell volume (1973)
    Springer
    Journal of molecular medicine 51 (1973), S. 141-142 
    Details
    ISSN: 1432-1440
    Keywords: Blood volume ; 99m-Tc-Pertechnetate ; 99m-Tc-Pertechnat ; Blutvolumen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Es wurden Untersuchungen zur Bestimmung des Erythrocytenvolumens beim Menschen mit dem kurzlebigen Isotop 99m-Tc durchgeführt. Dabei zeigte sich, daß eine ausreichend stabile Markierung durch halbstündige Inkubation mit 99m-Tc und anschließende kurzzeitige Zugabe von SnCl2 erreicht werden kann. Die Inkorporationsrate ist vom Plasmaanteil und vom Hämatokrit der zu markierenden Erythrocytensuspension abhängig. Gleichzeitige Markierung derselben oder einer gleichen Probe mit51Cr ergab gut übereinstimmende Resultate für das Erythrocytenvolumen.
    Notes: Summary Incubation of human red cells with 99 m-Tc and subsequent addition of SnCl2 resulted in stable red cell labeling. Simultaneous tagging of the same or another red cell specimen by51Cr and calculation of the red cell volume from both isotopes gave almost identical results. The 99m-Tc-technique may become the method of choice for red cell volume determination.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01483924
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...